


C. I. STATHAKIS\*, T. V. KOFTIS\* ET AL. (PHARMATHEN S.A., THESSALONIKI, GREECE)  
 (Chloromethyl)dimethylchlorosilane–KF: A Two-Step Solution to the Selectivity Problem in the Methylation of a  
 Pyrimidone Intermediate en Route to Raltegravir  
*Org. Process Res. Dev.* **2017**, *21*, 1413–1418.

## Synthesis of Raltegravir



**Significance:** Raltegravir potassium (Isentress®) is an HIV integrase inhibitor manufactured by Merck & Co. (G. R. Humphrey et al. *Org. Process Res. Dev.* **2011**, *15*, 73). A major challenge in the synthesis of raltegravir is the selective N-methylation of the pyrimidone intermediate **A**. Conventional methylating agents such as MeI produced mixtures of N- and O-methylated pyrimidones that were difficult to separate.

**Comment:** Highly selective N-methylation of **A** was achieved by the three-step sequence developed by workers at Pharmathen involving (1) N-alkylation of **B** with **C** to give **F**, (2) amidation of **F** with amine **G**, and (3) desilylation of **H** with potassium fluoride in methanol. By this procedure, the desired N-methylpyrimidone **I** was obtained in 82% overall yield on a 420 mmol scale. For a mechanism for the formation of **I**, see: V. A. Pestunovich and co-workers *J. Organomet. Chem.* **1989**, *361*, 147.

**SYNFACTS Contributors:** P. J. Kocienski  
 Synfacts 2017, 13(12), 1227 Published online: 17.11.2017  
 DOI: 10.1055/s-0036-1591624; Reg-No.: K05417SF